Shuttle Pharmaceuticals Holdings, INC 8-K filings

Shuttle Pharmaceuticals Holdings, Inc. has implemented a 1-for-10 reverse stock split effective June 11, 2026, to adjust its common stock structure.

Shuttle Pharmaceuticals Holdings announced the results of its 2026 Annual Meeting of Stockholders, with key proposals including director elections, auditor ratification, executive compensation advisory vote, and a reverse stock split authorization receiving approval.

Shuttle Pharmaceuticals Holdings, Inc. has finalized its merger with United Dogecoin Inc. and secured $9.55 million in PIPE financing.

Shuttle Pharmaceuticals Holdings, Inc. announced a definitive merger with United Dogecoin Inc. and an $11 million PIPE financing, aiming to become the largest publicly listed Dogecoin miner.

Shuttle Pharmaceuticals Holdings, Inc. has extended the consulting agreement for interim co-Chief Executive Officer Christopher Cooper through August 1, 2026.

Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Yuying Liang as Chief Financial Officer and the resignation of Sachin Pathigoda from its Board of Directors.

Shuttle Pharmaceuticals Holdings, Inc. amended an asset purchase agreement to accelerate a portion of its first installment payment through the issuance of 320,496 common shares.

Shuttle Pharmaceuticals Holdings, Inc. announced the immediate resignation of CFO Timothy Lorber, with Interim CEO Christopher Cooper assuming the CFO role temporarily.

Shuttle Pharmaceuticals Holdings, Inc. has acquired substantially all assets and liabilities of 1542770 BC Ltd., including AI-assisted drug discovery technology, for up to $10 million in cash and stock.

Shuttle Pharmaceuticals Holdings, Inc. announced the discontinuation of its Ropidoxuridine clinical trials and a $300,000 settlement with Theradex Systems, Inc.

Shuttle Pharmaceuticals Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a $2.5 million private placement.

Shuttle Pharmaceuticals Holdings, Inc. announced the closing of a private placement offering, raising approximately $2.5 million through the sale of pre-funded common stock purchase warrants.

Shuttle Pharmaceuticals Holdings, Inc. entered a binding term sheet to acquire Molecule's assets for $10 million while simultaneously facing the termination of its primary CRO agreement and a $1.091 million payment demand from Theradex Systems, Inc.

Shuttle Pharmaceuticals Holdings, Inc. has engaged IR Agency LLC for a two-month, $1.45 million marketing and advertising campaign aimed at the financial community.

Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Sachin Pathigoda and Angel Liriano as new directors, along with changes to committee chairmanships.

Shuttle Pharmaceuticals Holdings, Inc. announced the resignation of Joseph Tung from its board of directors, effective September 11, 2025.

Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Adam Chambers, principal of Bowery Consulting Group Inc., to its Board of Directors.

Steven Richards has resigned from the board of Shuttle Pharmaceuticals Holdings, Inc., with the company confirming no disputes over operations or policies.

Shuttle Pharmaceuticals Holdings, Inc. reported the immediate resignation of Peter Dritschilo from his roles as President, Chief Operating Officer, and Secretary.

Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a $4.25 million private placement of common stock and pre-funded warrants, with proceeds earmarked for potential acquisitions, marketing, and general corporate purposes.

Shuttle Pharmaceuticals Holdings, Inc. announced a significant 70% salary reduction for most salaried employees and executive officers, with its CFO's salary being deferred, signaling potential severe financial challenges.

Shuttle Pharmaceuticals reports the resignation of its Chief Scientific Officer and director, along with the results of its 2025 Annual Meeting of Stockholders.

Shuttle Pharmaceuticals will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, providing an update on its Phase 2 trial and Shuttle Diagnostics subsidiary.

Shuttle Pharmaceuticals announces the filing of a key provisional patent application for PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy, marking a critical advancement in its diagnostic program.

Shuttle Pharmaceuticals Holdings, Inc. has entered into a consulting agreement with IR Agency LLC for marketing and advertising services, agreeing to pay $2 million for a three-month term.

Shuttle Pharmaceuticals Holdings, Inc. announces a management restructuring, appointing an interim CEO and amending Dr. Anatoly Dritschilo's employment agreement to focus on scientific endeavors.

Shuttle Pharmaceuticals Holdings, Inc. has entered into a consulting agreement with Bowery Consulting Group Inc. to enhance its business strategy, investor relations, and capital-raising efforts.

Shuttle Pharmaceuticals Holdings, Inc. successfully closed a $5.75 million underwritten public offering to advance its Phase II clinical trial and bolster marketing efforts.

Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO to enhance capital markets and business capabilities, while Dr. Anatoly Dritschilo continues to oversee scientific and clinical trial activities.

Shuttle Pharmaceuticals Holdings, Inc. has entered into a Revolving Loan Agreement for up to $2 million to support general corporate purposes, including a potential public equity offering.